Myriad Genetics (MYGN) Common Equity (2010 - 2026)

Myriad Genetics has disclosed Common Equity across 17 years of filings, most recently posting $337.4 million for Q1 2026.

• In Q1 2026, Common Equity fell 52.14% year-over-year to $337.4 million; the TTM figure through Mar 2026 stood at $337.4 million (down 52.14% YoY), while the FY2025 annual figure was $368.0 million, down 47.51% from the prior year.
• Common Equity fell to $337.4 million in Q1 2026, from $368.0 million in the prior quarter.
• Over the last five years, Common Equity for MYGN reached as high as $950.1 million in Q1 2022 and fell as low as $337.4 million in Q1 2026.
• The 5-year median for Common Equity is $735.2 million (2023), against an average of $696.6 million.
• Annual changes were most pronounced in 2022 — Common Equity rose 8.56% — and 2026, when it sank 52.14%.
• A 5-year view of Common Equity shows it stood at $885.8 million in 2022, then retreated by 11.58% to $783.2 million in 2023, then dropped by 10.48% to $701.1 million in 2024, then slumped by 47.51% to $368.0 million in 2025, then slipped by 8.32% to $337.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $337.4 million, $368.0 million, and $372.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.